BRIEF—Lundbeck eyes growth with new US head

Danish neuroscience specialist Lundbeck has appointed Thomas Gibbs as executive vice president and head of the firm’s US business.

Mr Gibbs, who will take up the position next month, was formerly chief executive at Vectura, where he advanced the development and commercialization of an inhaled therapeutics portfolio.

He has also served as chief commercial officer at Sunovion and head of general medicines in the USA for Japanese pharma major Takeda.

Chief executive Deborah Dunsire said the appointment was key, “given the size and impact of the US market for Lundbeck,” and “the importance of the two launches we have there in 2023, as well as our ambitions to grow through both internal and external innovation.”